Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development

Keith Q. Tanis, Samuel Sathyanesan, Ronald S. Duman

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalCNS and Neurological Disorders - Drug Targets
Volume6
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Nerve Growth Factors
Antidepressive Agents
Intercellular Signaling Peptides and Proteins
Gene Expression
Atrophy
Up-Regulation
Brain
Therapeutics

Keywords

  • Cyclic AMP response element binding protein (CREB)
  • ERK Phosphorylation
  • GSK-3 Inhibitors
  • Mitogen-activated (MAP) kinase
  • Monoamine Receptor Agonists

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. / Tanis, Keith Q.; Sathyanesan, Samuel; Duman, Ronald S.

In: CNS and Neurological Disorders - Drug Targets, Vol. 6, No. 2, 01.04.2007, p. 151-160.

Research output: Contribution to journalReview article

@article{71c306b246fd48609c8352e8ab85b0e9,
title = "Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development",
abstract = "Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.",
keywords = "Cyclic AMP response element binding protein (CREB), ERK Phosphorylation, GSK-3 Inhibitors, Mitogen-activated (MAP) kinase, Monoamine Receptor Agonists",
author = "Tanis, {Keith Q.} and Samuel Sathyanesan and Duman, {Ronald S.}",
year = "2007",
month = "4",
day = "1",
doi = "10.2174/187152707780363276",
language = "English (US)",
volume = "6",
pages = "151--160",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development

AU - Tanis, Keith Q.

AU - Sathyanesan, Samuel

AU - Duman, Ronald S.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.

AB - Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.

KW - Cyclic AMP response element binding protein (CREB)

KW - ERK Phosphorylation

KW - GSK-3 Inhibitors

KW - Mitogen-activated (MAP) kinase

KW - Monoamine Receptor Agonists

UR - http://www.scopus.com/inward/record.url?scp=34247554341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247554341&partnerID=8YFLogxK

U2 - 10.2174/187152707780363276

DO - 10.2174/187152707780363276

M3 - Review article

VL - 6

SP - 151

EP - 160

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 2

ER -